About
Sepsis drug
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibody
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
2
As Collaborator
1
Total Enrollment
349
By Phase
PHASE2: 1PHASE1: 2
By Status
COMPLETED: 3
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
Today
Hover over trial bars to see details
Recent Trials
NCT03085758Lead Sponsor
Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB
PHASE2Completed
301 participants
Started: Dec 12, 2017 · Completed: Dec 20, 2019
NCT03083171Lead Sponsor
Adrecizumab-LPS Study
PHASE1Completed
24 participants
Started: Jan 4, 2017 · Completed: May 24, 2017
NCT02991508Collaborator
Adrecizumab Phase 1 Trial
PHASE1Completed
24 participants
Started: May 23, 2016 · Completed: Sep 22, 2016
Funding History (1)
D
Feb 19, 2025
Locations (1)
Headquarters
Hennigsdorf, Germany
Map
Loading map...